TY - JOUR
T1 - Pre-targeting with ultra-small nanoparticles
T2 - Boron carbon dots as drug candidates for boron neutron capture therapy
AU - Feiner, Irene V.J.
AU - Pulagam, Krishna R.
AU - Uribe, Kepa B.
AU - Passannante, Rossana
AU - Simó, Cristina
AU - Zamacola, Kepa
AU - Gómez-Vallejo, Vanessa
AU - Herrero-Álvarez, Natalia
AU - Cossío, Unai
AU - Baz, Zuriñe
AU - Caffarel, María M.
AU - Lawrie, Charles H.
AU - Vugts, Danielle J.
AU - Rejc, Luka
AU - Llop, Jordi
N1 - Funding Information: Financial support for this work was provided by the European Commission under the H2020-MSCA-ITN-2015 program (grant agreement no. 675417) and the Spanish Ministry of Economy and Competitiveness (CTQ2017-87637-R). The work was performed as part of the Maria de Maeztu Units of Excellence Program (Grant No. MDM-2017-0720). Publisher Copyright: © The Royal Society of Chemistry.
PY - 2021/1/14
Y1 - 2021/1/14
N2 - Boron neutron capture therapy (BNCT) is a promising cancer treatment exploiting the neutron capture capacity and subsequent fission reaction of boron-10. The emergence of nanotechnology has encouraged the development of nanocarriers capable of accumulating boron atoms preferentially in tumour cells. However, a long circulation time, required for high tumour accumulation, is usually accompanied by accumulation of the nanosystem in organs such as the liver and the spleen, which may cause off-target side effects. This could be overcome by using small-sized boron carriers via a pre-targeting strategy. Here, we report the preparation, characterisation and in vivo evaluation of tetrazine-functionalised boron-rich carbon dots, which show very fast clearance and low tumour uptake after intravenous administration in a mouse HER2 (human epidermal growth factor receptor 2)-positive tumour model. Enhanced tumour accumulation was achieved when using a pretargeting approach, which was accomplished by a highly selective biorthogonal reaction at the tumour site with trans-cyclooctene-functionalised Trastuzumab. This journal is
AB - Boron neutron capture therapy (BNCT) is a promising cancer treatment exploiting the neutron capture capacity and subsequent fission reaction of boron-10. The emergence of nanotechnology has encouraged the development of nanocarriers capable of accumulating boron atoms preferentially in tumour cells. However, a long circulation time, required for high tumour accumulation, is usually accompanied by accumulation of the nanosystem in organs such as the liver and the spleen, which may cause off-target side effects. This could be overcome by using small-sized boron carriers via a pre-targeting strategy. Here, we report the preparation, characterisation and in vivo evaluation of tetrazine-functionalised boron-rich carbon dots, which show very fast clearance and low tumour uptake after intravenous administration in a mouse HER2 (human epidermal growth factor receptor 2)-positive tumour model. Enhanced tumour accumulation was achieved when using a pretargeting approach, which was accomplished by a highly selective biorthogonal reaction at the tumour site with trans-cyclooctene-functionalised Trastuzumab. This journal is
UR - http://www.scopus.com/inward/record.url?scp=85099755873&partnerID=8YFLogxK
U2 - https://doi.org/10.1039/d0tb01880e
DO - https://doi.org/10.1039/d0tb01880e
M3 - Article
C2 - 33367431
SN - 2050-750X
VL - 9
SP - 410
EP - 420
JO - Journal of Materials Chemistry B
JF - Journal of Materials Chemistry B
IS - 2
ER -